This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Quality of Life  • Neoplasms  • Phototherapy  • Drug Therapy  • Drug Therapy, Other  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Alert me on articles by topic

Marie-France Demierre, MD; Pascal Ferzli, MD; Donald Miller, ScD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In a prospective pilot study, we investigated whether the combination of Skindex-29^1-2 and Functional Assessment of Cancer Therapy–General scale (FACT-G)^{1, 3} provided relevant information during therapy on health-related quality of life (HRQOL) that would not be obtained from clinical assessment of patients with mycosis fungoides and/or Sézary syndrome (MF/SS).

Methods

Informed consent was obtained from 11 adult patients, 5 women and 6 men, with a confirmed diagnosis of MF/SS, evaluated at Boston Medical Center. Demographics, stage of disease, number of prior treatments, percentage of Sézary cells, and CD4/CD8 ratio were recorded. Weighted skin scores,⁴ pruritus visual analog scale,⁴ and a patient-completed disease severity score⁵ were obtained for all patients, as were completed FACT-G (version 4)^{1, 3} and Skindex-29^1-2 questionnaires at baseline and at each visit.

Scale and total instrument scores at baseline and at follow-up were calculated for the total sample and in patients . . . [Full Text of this Article]

Results

Comment

AUTHOR INFORMATION